Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2 breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab treatment is uncle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2020-02, Vol.26 (3), p.738-745
Hauptverfasser:	De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C, Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G, Trivedi, Meghana V, Cataldo, Maria Letizia, Pavlick, Anne, Wolff, Antonio C, Weigelt, Britta, Reis-Filho, Jorge S, Prat, Aleix, Gutierrez, Carolina, Osborne, Charles Kent, Rimawi, Mothaffar F, Schiff, Rachel
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - immunology Breast Neoplasms - metabolism Breast Neoplasms - pathology Female Follow-Up Studies Humans Lapatinib - administration & dosage Lymphocytes - drug effects Lymphocytes - immunology Lymphocytes, Tumor-Infiltrating - drug effects Lymphocytes, Tumor-Infiltrating - immunology Middle Aged Neoadjuvant Therapy - methods Prognosis Receptor, ErbB-2 - immunology Receptor, ErbB-2 - metabolism Trastuzumab - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!